Management of chronic myeloid leukemia during pregnancy: a retrospective analysis at a single center
Hematol., Transfus. Cell Ther. (Impr.)
;
41(2): 125-128, Apr.-June 2019. tab
Article
Dans Anglais
| LILACS
| ID: biblio-1012180
ABSTRACT
ABSTRACT We analyzed the management and outcomes of pregnancies of patients with chronic myeloid leukemia at a single center over fifteen years. Among the 203 CML female patients, there were ten pregnancies in seven women, all of them not planned. In three cases, the chronic myeloid leukemia diagnosis was made during pregnancy. Five patients received tyrosine kinase inhibitors in the first weeks of pregnancy and the drug was interrupted until delivery. One patient lost complete cytogenetic response, and two patients lost the hematological response. A patient with a stable major molecular response had two successful pregnancies without loss of response. There were four premature births. There were no maternal adverse events, fetal malformation or death. All patients received Interferon-alpha during gestation, and two received hydroxyurea for a short period. Leukapheresis was performed in two patients for hyperleukocytosis control. One patient with sickle cell disease died from disease progression six months after delivery. Conclusions:
The tyrosine kinase inhibitors ministration should be interrupted during pregnancy. Patients should be advised to achieve a stable and deep molecular response if they plan to conceive, to avoid the risk of disease progression.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Grossesse
/
Leucémie myéloïde chronique BCR-ABL positive
/
Interféron alpha
/
Mésilate d'imatinib
/
Dasatinib
/
Hydroxy-urée
Type d'étude:
Facteurs de risque
Limites du sujet:
Femelle
/
Humains
/
Grossesse
langue:
Anglais
Texte intégral:
Hematol., Transfus. Cell Ther. (Impr.)
Thème du journal:
Hematologia
/
TransfusÆo de Sangue
Année:
2019
Type:
Article
Pays d'affiliation:
Brésil
Institution/Pays d'affiliation:
Universidade Estadual de Campinas/BR
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS